New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 25, 2014
06:04 EDTAGN, SRPTStocks with implied volatility below IV index mean; AGN MNKD
Stocks with implied volatility below IV index mean; Allergan (AGN) 29, MannKind (MNKD) 75 according to iVolatility.
News For AGN;SRPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 17, 2014
09:43 EDTAGNValeant not going to raise Allergan bid ahead of meeting, CNBC reports
Subscribe for More Information
09:17 EDTSRPTOn The Fly: Pre-market Movers
Subscribe for More Information
October 16, 2014
18:36 EDTSRPTOn The Fly: After Hours Movers
Subscribe for More Information
18:16 EDTSRPTSarepta up 10.6% following publication of Ebola phase 1 clinical study
16:13 EDTSRPTSarepta announces publication of Ebola, Marburg Phase I clinical study results
Sarepta Therapeutics announced the publication of results from two single ascending-dose studies that demonstrated no clinical or toxicologic safety concerns with the company’s drug candidates for the treatment of Ebola and Marburg virus, respectively. AVI-6002 for the treatment of Ebola is a combination therapy of two phosphorodiamidate morpholino oligomers, which target the viral matrix proteins VP24 and VP35, respectively. AVI-6003 for the treatment of Marburg is a combination therapy of two PMOs, which target the viral proteins VP24 and NP, respectively. These drug candidates use Sarepta’s advanced and proprietary PMOplus chemistry, which is also the basis of the company’s clinical-stage influenza drug candidate, AVI-7100. Results from previous viral challenge studies of AVI-6002 and AVI-6003 in non-human primates demonstrated prevention of disease development and death following exposure to Ebola or Marburg virus. Subsequent animal studies demonstrated that for each combination therapy, only one oligomer contributed to efficacy, and therefore, the lead drug candidates for Ebola and Marburg have since become the single compounds AVI-7537 and AVI-7288.
12:42 EDTAGNAckman believes Allergan, Valeant merger likely, CNBC reports
Subscribe for More Information
12:38 EDTAGNAckman says Allergan CEO manipulated Valeant shares, CNBC reports
Subscribe for More Information
08:58 EDTAGNAllergan was pressured by AbbVie news, says BMO Capital
Subscribe for More Information
07:23 EDTAGNIBF Conferences to hold a summit
Ophthalmology Innovation Summit is being held in Chicago on October 16.
October 15, 2014
15:00 EDTAGNShire-Allergan, AbbVie-Pfizer deals possible if merger scrapped, Bloomberg says
Subscribe for More Information
13:07 EDTAGNAllergan seeing arb-related selling pressure, says BMO Capital
Subscribe for More Information
10:49 EDTSRPTEbola linked names rise again amid broader market sell-off
Subscribe for More Information
October 14, 2014
09:04 EDTSRPTChinese company says drug can cure Ebola, Reuters reports
Subscribe for More Information
06:03 EDTAGNMarket overreacted to new Irish tax rules, says BMO Capital
BMO Capital believes the market may have overreacted yesterday to the report that Ireland is eliminating the "Double Irish" tax loophole. The firm says Allergan (AGN) confirmed that it incorporated potential changes to Irish tax law in its recently raised earnings guidance while Mallinckrodt (MNK) said it does expect the new tax structure to have an immediate impact. BMO views yesterday's pullback in shares of Allergan, Mallinckrodt and Actavis (ACT) as an overreaction.
October 13, 2014
12:44 EDTSRPTSarepta data supported by DMD study in journal, TheStreet reports
A study published in medical journal PLOS One following the progression of Duchenne muscular dystrophy supports Sarepta's push for accelerated approval of eteplirsen, TheStreet's Adam Feuerstein reports. Reference Link
06:39 EDTAGNAllergan takeout value at or above $210 per share, says Leerink
Leerink believes Allergan's takeover value is now at or above $210 per share given the company's recent execution. After speaking with management, the firm says Allergan's upside in Q3 was driving by fundamentals, not cost cuts. It continues to view the "most likely and straightforward outcome" for Allergan as being an outright sale of the company. Leerink raised its price target for shares to $215 from $184 and keeps an Outperform rating on Allergan.
October 12, 2014
19:26 EDTSRPTPatient being evaluated at Boston hospital for possible Ebola, Boston Globe says
Health officials say that a man that recently traveled to Liberia is being assessed at Beth Israel Deaconess hospital in Boston for the Ebola virus, the Boston Globe says. Drug companies that are working on experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Reference Link
19:12 EDTSRPTCDC confirms Texas healthcare worker positive for Ebola
Subscribe for More Information
14:18 EDTSRPTNY's JFK Airport begins Ebola screenings, WSJ says
Subscribe for More Information
12:48 EDTSRPTTexas health-care worker tests positive for Ebola, WSJ says
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use